We rank companies based on fund manager, research analyst and news sentiment
AVTX stock icon

Avalo Therapeutics, Inc. Common Stock


About: Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Employees: 19

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %
of 7 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

32% more capital invested

Capital invested by funds: $159K [Q3] → $209K (+$50.4K) [Q4]

6.38% less ownership

Funds ownership: 6.4% [Q3] → 0.01% (-6.38%) [Q4]

57% less funds holding

Funds holding: 28 [Q3] → 12 (-16) [Q4]

84% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 19

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 9

Research analyst outlook

We haven’t received any recent analyst ratings for AVTX.

Financial journalist opinion

Based on 7 articles about AVTX published over the past 30 days